BIOQUAL FY2026 Revenue Drops 18%, Net Loss Widens to $4.2M
BIOQ is trading near its 52-week low of $32.5 (1.5% above the low) on elevated volume (1.9× avg).
Summary
BIOQUAL reported FY2026 revenue of $39.9M, down 18% from $48.9M in FY2025. Net loss widened to $4.17M from $1.05M, with EPS of -$4.08 versus -$1.17. The company is trading near its 52-week low of $32.5, and these results confirm deteriorating fundamentals. The loss before income tax also expanded to $3.7M from $1.3M. With a market cap of only $29.5M, the magnitude of the loss is material. The company cites risks around government contracts and animal model demand, but no specific guidance was provided.
At the time of this announcement, BIOQ was trading at $33.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $29.5M. The 52-week trading range was $32.50 to $108.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.